{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:10:43Z","timestamp":1779379843548,"version":"3.53.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fujian\u00a0Provincial\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","award":["2022J05328"],"award-info":[{"award-number":["2022J05328"]}]},{"name":"Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0Shanghai","award":["23ZR1459100"],"award-info":[{"award-number":["23ZR1459100"]}]},{"name":"Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0Shanghai","award":["22ZR1457900"],"award-info":[{"award-number":["22ZR1457900"]}]},{"DOI":"10.13039\/501100001809","name":"National\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["82272772"],"award-info":[{"award-number":["82272772"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["82372832"],"award-info":[{"award-number":["82372832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["82273289"],"award-info":[{"award-number":["82273289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key\u00a0Discipline\u00a0Construction\u00a0Project\u00a0of\u00a0Medicine\u00a0in\u00a0Shanghai\u00a0Xuhui\u00a0District","award":["SHXHZDXK202304"],"award-info":[{"award-number":["SHXHZDXK202304"]}]},{"name":"Research\u00a0Projects\u00a0from\u00a0the\u00a0Science\u00a0and\u00a0Technology\u00a0Commission\u00a0of\u00a0Shanghai\u00a0Municipality","award":["21JC1401202"],"award-info":[{"award-number":["21JC1401202"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Biliary tract cancer (BTC) is typically diagnosed at an advanced stage due to the lack of effective screening tools, resulting in limited therapeutic options and poor survival outcomes. Therefore, there is a critical need for non-invasive strategies that enable early detection and risk stratification. Fragmentomic profiling of cell-free DNA (cfDNA) captures genome-wide fragmentation patterns reflecting tumor-associated chromatin structure and genomic instability, providing a promising approach for non-invasive cancer detection. In this study, we developed a low-pass whole-genome sequencing (WGS)-based framework for BTC detection and postoperative risk assessment. Plasma samples were analyzed to derive three fragmentomic features, including copy number variation, fragment size distribution, and promoter fragmentation entropy, which were integrated into a machine-learning model trained using five-fold cross-validation. The model demonstrated robust performance across independent validation cohorts, outperforming individual fragmentomic features and conventional serum biomarkers, and accurately distinguished BTC from benign biliary diseases. Longitudinal analyses revealed that cfDNA fragmentomic risk scores dynamically tracked disease burden and treatment response. Importantly, postoperative risk scores were independently associated with disease-free survival, highlighting their prognostic value. Collectively, these findings establish a scalable and cost-effective framework for cfDNA-based BTC detection and monitoring using low-pass WGS data. This approach shows strong potential for targeted screening in high-risk populations and for guiding personalized postoperative surveillance and clinical management for BTC patients.<\/jats:p>","DOI":"10.1186\/s43556-026-00468-7","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:27:52Z","timestamp":1779334072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Noninvasive detection and prognostic stratification of biliary tract cancer using cell-free DNA fragmentomics: a model development and validation study"],"prefix":"10.1186","volume":"7","author":[{"given":"Jiwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruowei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7144-231X","authenticated-orcid":false,"given":"Houbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"10272","key":"468_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(21)00153-7.","journal-title":"Lancet"},{"issue":"2","key":"468_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"issue":"6","key":"468_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108489","volume":"51","author":"K Soreide","year":"2025","unstructured":"Soreide K, Dopazo C, Berrevoet F, Carrion-Alvarez L, Diaz-Nieto R, Andersson B, et al. Biliary tract cancer. Eur J Surg Oncol. 2025;51(6):108489. https:\/\/doi.org\/10.1016\/j.ejso.2024.108489.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"468_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20(7):470\u201386. https:\/\/doi.org\/10.1038\/s41571-023-00770-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"468_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"468_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/HEP.0000000000001200","volume":"82","author":"QT Vu","year":"2025","unstructured":"Vu QT, Nishimura Y, Harada K, Ito H, Higashionna T, Maruo A, et al. International trends in biliary tract cancer-related mortality, 2000-2022: an observational study of the World Health Organization mortality database. Hepatology. 2025;82(3):626\u201337. https:\/\/doi.org\/10.1097\/HEP.0000000000001200.","journal-title":"Hepatology"},{"issue":"1","key":"468_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-04121-5","volume":"25","author":"F Dai","year":"2025","unstructured":"Dai F, Luo H, Cai Y, Dai Y. Global burden, temporal trends, and health workforce correlations of gallbladder and biliary tract cancer: a comprehensive analysis from 1990 to 2021 with projections to 2046. BMC Gastroenterol. 2025;25(1):596. https:\/\/doi.org\/10.1186\/s12876-025-04121-5.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"468_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","volume":"51","author":"M Qurashi","year":"2025","unstructured":"Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2025;51(2):107064. https:\/\/doi.org\/10.1016\/j.ejso.2023.107064.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"468_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-2004-828891","volume":"24","author":"O Nehls","year":"2004","unstructured":"Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis. 2004;24(2):139\u201354. https:\/\/doi.org\/10.1055\/s-2004-828891.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"468_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3748\/wjg.v10.i3.427","volume":"10","author":"XL Qin","year":"2004","unstructured":"Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol. 2004;10(3):427\u201332. https:\/\/doi.org\/10.3748\/wjg.v10.i3.427.","journal-title":"World J Gastroenterol"},{"issue":"9935","key":"468_CR11","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma Lancet. 2014;383(9935):2168\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0.","journal-title":"Cholangiocarcinoma Lancet"},{"key":"468_CR12","doi-asserted-by":"publisher","unstructured":"Macias RIR, Banales JM, Sangro B, Muntane J, Avila MA, Lozano E et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1468\u201377. https:\/\/doi.org\/10.1016\/j.bbadis.2017.08.002.","DOI":"10.1016\/j.bbadis.2017.08.002"},{"issue":"5","key":"468_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-19-0622","volume":"10","author":"P Jiang","year":"2020","unstructured":"Jiang P, Sun K, Peng W, Cheng SH, Ni M, Yeung PC, et al. Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discov. 2020;10(5):664\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0622.","journal-title":"Cancer Discov"},{"issue":"1","key":"468_CR14","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12(1):5060. https:\/\/doi.org\/10.1038\/s41467-021-24994-w.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"468_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016;164(1\u20132):57\u201368. https:\/\/doi.org\/10.1016\/j.cell.2015.11.050.","journal-title":"Cell"},{"issue":"6","key":"468_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745\u201359. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011.","journal-title":"Ann Oncol"},{"issue":"4","key":"468_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41587-021-01207-9","volume":"40","author":"P Jiang","year":"2022","unstructured":"Jiang P, Lo YMD. Enhanced cancer detection from cell-free DNA. Nat Biotechnol. 2022;40(4):473\u20134. https:\/\/doi.org\/10.1038\/s41587-021-01207-9.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"468_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol. 2022;40(4):585\u201397. https:\/\/doi.org\/10.1038\/s41587-022-01222-4.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"468_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.20892\/j.issn.2095-3941.2023.0159","volume":"21","author":"J Li","year":"2023","unstructured":"Li J, Lan X. Perspective on new cell-free DNA technologies for early cancer detection. Cancer Biol Med. 2023;21(2):139\u201343. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0159.","journal-title":"Cancer Biol Med"},{"key":"468_CR20","doi-asserted-by":"publisher","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W et al. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer. 2023;12(5):405\u201344. https:\/\/doi.org\/10.1159\/000530495.","DOI":"10.1159\/000530495"},{"key":"468_CR21","doi-asserted-by":"publisher","unstructured":"Kazi IA, Jahagirdar V, Kabir BW, Syed AK, Kabir AW, Perisetti A. Role of Imaging in Screening for Hepatocellular Carcinoma. Cancers (Basel). 2024;16(19). https:\/\/doi.org\/10.3390\/cancers16193400.","DOI":"10.3390\/cancers16193400"},{"issue":"3","key":"468_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jacr.2024.10.014","volume":"22","author":"M Mohnasky","year":"2025","unstructured":"Mohnasky M, Gad S, Moon A, Barritt AS, Charalel RA, Eckblad C, et al. Hepatocellular Carcinoma Screening: From Current Standard of Care to Future Directions. J Am Coll Radiol. 2025;22(3):260\u20138. https:\/\/doi.org\/10.1016\/j.jacr.2024.10.014.","journal-title":"J Am Coll Radiol"},{"issue":"9","key":"468_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"468_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167\u201377. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.806.","journal-title":"Ann Oncol"},{"key":"468_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03735-2","author":"H Bao","year":"2025","unstructured":"Bao H, Yang S, Chen X, Dong G, Mao Y, Wu S, et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03735-2.","journal-title":"Nat Med"},{"key":"468_CR26","doi-asserted-by":"publisher","unstructured":"Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. https:\/\/doi.org\/10.1126\/scitranslmed.aab0021.","DOI":"10.1126\/scitranslmed.aab0021"},{"issue":"7655","key":"468_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446\u201351. https:\/\/doi.org\/10.1038\/nature22364.","journal-title":"Nature"},{"issue":"14","key":"468_CR28","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3663.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"468_CR29","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3616.","journal-title":"JAMA Oncol"},{"issue":"4","key":"468_CR30","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabieres","year":"2021","unstructured":"Alix-Panabieres C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1311.","journal-title":"Cancer Discov"},{"issue":"1","key":"468_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6003-8","volume":"19","author":"N Wan","year":"2019","unstructured":"Wan N, Weinberg D, Liu TY, Niehaus K, Ariazi EA, Delubac D, et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. BMC Cancer. 2019;19(1):832. https:\/\/doi.org\/10.1186\/s12885-019-6003-8.","journal-title":"BMC Cancer"},{"issue":"1","key":"468_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y.","journal-title":"Nat Commun"},{"issue":"4","key":"468_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2023.110662","volume":"115","author":"S Su","year":"2023","unstructured":"Su S, Xuan Y, Fan X, Bao H, Tang H, Lv X, et al. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection. Genomics. 2023;115(4):110662. https:\/\/doi.org\/10.1016\/j.ygeno.2023.110662.","journal-title":"Genomics"},{"issue":"7761","key":"468_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385\u20139. https:\/\/doi.org\/10.1038\/s41586-019-1272-6.","journal-title":"Nature"},{"issue":"3","key":"468_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1212","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Sun X, Yang H, Chen J, Bu Z, Ji J, et al. Integrated analysis toolkit for dissecting whole-genome-wide features of cell-free DNA. Clin Transl Med. 2023;13(3):e1212. https:\/\/doi.org\/10.1002\/ctm2.1212.","journal-title":"Clin Transl Med"},{"key":"468_CR36","unstructured":"LeDell E, Poirier S. H2O AutoML: Scalable Automatic Machine Learning. 7th ICML Workshop on Automated Machine Learning (AutoML).July 2020. Available at: https:\/\/www.automl.org\/wp-content\/uploads\/2020\/07\/AutoML_2020_paper_61.pdf"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00468-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00468-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00468-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:02:15Z","timestamp":1779379335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00468-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00468-7","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (Approval No. B2023\u2014299R2) and The Third Affiliated Hospital of Sun Yat-Sen University (Approval No. II2024\u2014378\u201401). Informed consent was obtained from all participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.W., H.B.1, D.Z., Q.X., H.B.2, R.Y., S.C., X.X., and X.W. are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}